FDA clears Orthovita's VITOMATRIX Bone Graft Substitute for dental procedures

Oct 4 2010

Orthovita, Inc. (NASDAQ: VITA), an orthobiologics and biosurgery company, announced that it received 510(k) clearance from the U.S. Food and Drug Administration to market VITOMATRIX Bone Graft Substitute as a bone grafting material in certain dental procedures.

VITOMATRIX is a resorbable, highly porous synthetic scaffold that utilizes the core proprietary technology from our VITOSS™ Bone Graft Substitute product line. VITOMATRIX is indicated for use in procedures to fill, augment or reconstruct periodontal or bony defects of the oral and maxillofacial region. An estimated 375,000 procedures are performed domestically each year where VITOMATRIX can be used.

Orthovita is evaluating potential commercial partners to distribute the product or license its underlying technology.